GlaxoSmithKline Pakistan Limited (PSX:GLAXO)

Pakistan · Delayed Price · Currency is PKR

373.01

+2.79 (0.75%)

At close: Jul 10, 2026

-7.17% (1Y)

Market Cap	118.79B +0.6%
Revenue (ttm)	67.35B +10.1%
Net Income	10.51B +29.8%
EPS	33.00 +29.8%
Shares Out	318.47M
PE Ratio	11.30
Forward PE	10.37
Dividend	17.00 (4.59%)
Ex-Dividend Date	Apr 24, 2026

Volume	187,081
Open	372.00
Previous Close	370.22
Day's Range	372.00 - 376.50
52-Week Range	293.09 - 459.94
Beta	0.41
Analysts	Strong Buy
Price Target	517.50 (+38.74%)
Earnings Date	Aug 24, 2026

About GlaxoSmithKline Pakistan

GlaxoSmithKline Pakistan Limited, a biopharma company, engages in the discovery, development, and delivery of medicines and vaccines in Pakistan. It offers products in the anti-infective, dermatology, respiratory, immunology and inflammation, oncology, infectious diseases, HIV, and vaccines therapy areas. The company sells its products under the Augmentin, Velosef, Amoxil, Dermovate, Clobevate, Betnovate, Calpol, Shingrix, and Cutivate brands. It also exports its products. The company was founded in 2001 and is headquartered in Karachi, Pakista... [Read more]

Industry Pharmaceuticals

Sector Healthcare

Founded 2001

Employees 1,606

Stock Exchange Pakistan Stock Exchange

Ticker Symbol GLAXO

Full Company Profile

Financial Performance

In 2025, GlaxoSmithKline Pakistan's revenue was 65.90 billion, an increase of 7.70% compared to the previous year's 61.19 billion. Earnings were 10.03 billion, an increase of 53.38%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for GLAXO stock is "Strong Buy." The 12-month stock price target is Rs 517.50, which is an increase of 38.74% from the latest price.

Price Target

Rs 517.50

(38.74% upside)

Analyst Consensus: Strong Buy

Stock Forecasts